BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20260515T233500
CREATED:20240103T125432Z
LAST-MODIFIED:20240103T131021Z
UID:38428-1713830400-1714089599@www.pharmajournalist.com
SUMMARY:5th TCR-based Therapies for Solid Tumors Summit
DESCRIPTION:The 5th TCR-based Therapies for Solid Tumors Summit returns is back as the exclusive gathering where TCR pipelines take center stage. It serves as the premier platform for networking with biopharma industry leaders dedicated to expediting the clinical and commercial development of TCR-based therapeutics. \nThis summit serves as the epicenter for exploring these transformative advancements\, poised to showcase the long-term efficacy of TCR therapies in the treatment of solid tumors\, marking a monumental milestone in the field’s evolution. \nThis is your opportunity to accelerate next generation TCR engineering\, enhance target identification\, & improve solid tumor persistence to transform clinical & scalable development for patients in need. Join TScan Therapeutics\, Marengo Therapeutics\, T-Cypher Bio and more to gain invaluable insights into the future of TCR-based therapies. \nFind out more here: https://ter.li/f8jhfw
URL:http://www.pharmajournalist.com/event/5th-tcr-based-therapies-for-solid-tumors-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20260515T233500
CREATED:20240117T110146Z
LAST-MODIFIED:20240131T105720Z
UID:38516-1713830400-1714089599@www.pharmajournalist.com
SUMMARY:2nd mRNA Process Development & Manufacturing Summit Europe
DESCRIPTION:As European biopharma seek regulatory clarity to progress their mRNA process development and manufacturing\, the 2nd mRNA Process Development & Manufacturing Summit Europe returns to help you improve and optimise purification processes\, platforms for circular and saRNAs and drug product formulation. \nWhere: Crowne Plaza Frankfurt – Congress Hotel\, Frankfurt\, Germany \nWhen: 23-25th April\, 2024 \nWebsite: https://ter.li/d3ggdb \n \nReuniting directors\, heads and senior scientists pioneering the European mRNA space\, this three-day industry forum will navigate key bottlenecks from mRNA sequence design to in vitro transcription and scaling up processes. \n\nGain clarity on regulatory quality standards and comparability changes with the MHRA and CureVac\nExplore continuous platform technologies to accelerate low cost manufacturing\nGlean insights into purification and computational modelling approaches to optimise downstream processes\nHarness platform technologies for circular and self-amplifying RNAs to enhance their manufacturability\nImprove your drug product formulation and manufacturing for personalised mRNA-based medicines\n\nWhat’s next:  \n\nDownload your copy of the brochure: https://ter.li/d3ggdb\nRegister your place: https://ter.li/lzwg6z
URL:http://www.pharmajournalist.com/event/2nd-mrna-process-development-manufacturing-summit-europe/
LOCATION:Crowne Plaza Frankfurt – Congress Hotel\, Lyoner Str. 44 -48\, Frankfurt am Main\, 60528\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20260515T233500
CREATED:20240123T114632Z
LAST-MODIFIED:20240126T122455Z
UID:38558-1713830400-1714089599@www.pharmajournalist.com
SUMMARY:Exosome Characterization & Analytical Development Summit
DESCRIPTION:In the ever-evolving exosome field\, the past year has witnessed remarkable progress. From Kimera’s FDA IND approval to Brexogen’s recent deal with HK inno.N and advancements in analytical technology\, the landscape is rapidly advancing. Developing robust techniques is increasingly crucial\, serving as the cornerstone for exosome therapeutics\, alongside drug delivery applications and advancements. \n \nThe Exosome Characterization & Analytical Development Summit offers a comprehensive forum\, equipping you with the skills needed to establish robust techniques\, select the best instruments\, ensure quality\, and seamlessly navigate regulatory processes. \nAcross three days in April\, this hotly anticipated summit will unite key experts from AbbVie\, Aegle Therapeutics\, Vesigen Therapeutics\, and more to unite an industry on: \n\nIn depth technical content of exosome analysis and parameters for confidence in quality\nDefining standardized tools and techniques while keeping regulatory guidance in mind for clinical progression\nBridging communications and networking between Analytical Experts and Decision Makers\n\nTo learn more\, and secure your place\, check out the official event website here: https://ter.li/v1xubp \nDownload the full event guide here: https://ter.li/182ula
URL:http://www.pharmajournalist.com/event/exosome-characterization-analytical-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240423
DTEND;VALUE=DATE:20240426
DTSTAMP:20260515T233500
CREATED:20240213T103635Z
LAST-MODIFIED:20240213T103635Z
UID:38695-1713830400-1714089599@www.pharmajournalist.com
SUMMARY:Peptide Based Therapeutics Summit
DESCRIPTION:Positioned in the goldilocks spot between small molecules and biologics\, peptide therapeutics have undergone an exciting uphill trajectory within the last decade. Fuelled by advances in synthesis and screening technologies\, together with novel design and delivery strategies to surmount their inherent drawbacks\, this modality is showing new levels of promise. The momentum behind this exciting modality is evidenced in the billion-dollar deals from industry giants such as Genentech and Merck\, signalling a surge in interest from an expanding array of companies venturing into the field of next-generation peptide-based drugs. \nThe first industry-focused event dedicated towards this exciting new modality\, the Peptide Based Therapeutics Summit will unite pioneers from Johnson & Johnson\, Fog Pharma\, Genentech & PeptiDream\, spanning diverse diseases and therapeutic approaches. Whether you’re focused on peptide-drug conjugates\, bicyclic or macro-cyclic peptides\, PCSK9\, GLP\, or any other peptide based therapeutic\, this is an invaluable opportunity to learn from peers\, accelerate discovery and de-risk the development of your peptide therapeutics. \nAs we enter the third wave of peptide-based therapeutics\, this therapeutic and disease agnostic meeting will bring together the leading minds in early discovery\, pre-formulation\, heads of peptide drug development and pioneering peptide chemists. Together\, we will dissect challenges related to improving peptide stability\, raising oral bioavailability and balancing cell permeability with intracellular target selectivity\, as well as exploring how the latest cutting-edge technology can help you arrive at the optimal lead compound. \nLearn more about this meeting that helps to shape the trajectory of these remarkable drugs across various therapeutic landscapes: https://ter.li/2qs54c
URL:http://www.pharmajournalist.com/event/peptide-based-therapeutics-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR